Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6791471 | 0.83 | SIGMAR1 (0.30) | SIGMAR1 | |
| SCHEMBL6787179 | 0.81 | LMNA (0.38) | SIGMAR1 | |
| SCHEMBL5228957 | 0.72 | CCNA2 (0.42) | SIGMAR1 | |
| SCHEMBL6794606 | 0.70 | CCNA2 (0.40) | SIGMAR1 | |
| SCHEMBL4263111 | 0.70 | SIGMAR1 (0.32) | SIGMAR1 | |
| SCHEMBL5228949 | 0.68 | EP300 (0.41) | — | |
| SCHEMBL5234460 | 0.66 | SIGMAR1 (0.37) | SIGMAR1 | |
| SCHEMBL13852037 | 0.65 | SIGMAR1 (0.33) | SIGMAR1 | |
| SCHEMBL4260846 | 0.64 | SIGMAR1 (0.36) | SIGMAR1 | |
| SCHEMBL6797609 | 0.64 | SIGMAR1 (0.36) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | SIGMAR1 4084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.